Vascular endothelial growth factor (VEGF)-C and VEGF-D require proteolytic cleavage of the carboxy terminal silk-homology domain for activation.
T he 5 mammalian vascular endothelial growth factor (VEGF) family members identified to date, VEGF (VEGF-A), VEGF-B, VEGF-C, VEGF-D, and placenta growth factor, are key regulators of physiological and pathological vasculogenesis, hematopoiesis, angiogenesis, lymphangiogenesis, and vascular permeability. 1,2 VEGF binds to VEGF receptor (VEGFR)-1 and VEGFR-2 and is a potent growth factor for blood vessel formation. 1 Furthermore, placenta growth factor, which activates only VEGFR-1, stimulates angiogenesis, 3 whereas the angiogenic activity of VEGF-B, which binds to the same receptor, is still under investigation. The biological properties of the VEGFs have been under extensive study, as these molecules are attractive when considering therapeutic angiogenesis, eg, in settings of tissue ischemia. 4 VEGF-C and VEGF-D have been shown to activate VEGFR-3 and to induce lymphangiogenesis in various in vivo models. [5] [6] [7] [8] [9] All members of the VEGF family have a modular domain structure, with the growth factor domain that binds to and activates the receptor, and accessory domains that are mostly involved with binding to the neuropilin receptors and pericellular matrix. 1 There are, however, striking differences in the accessory domains. VEGF is expressed as multiple splice variants, including the major forms VEGF 121 , VEGF 165 , and VEGF 189 . These encode proteins that differ in the carboxy terminal (CT) accessory domain. The region of VEGF binding to heparin and heparan-sulfate is coded by exons 6 and 7. Exon 7 also encodes a sequence responsible for binding to neuropilin-1 (NP-1). 10 Neuropilins are transmembrane proteins that have a short cytoplasmic domain, and they were first characterized in the nervous system, where they regulate axon growth. NP-1 and NP-2 form complexes with semaphorins, plexins, VEGF family members and VEGF receptors. 11 NP-1, which increases the bioactivity of VEGF, is expressed in arteries, whereas NP-2 is mainly expressed in lymphatic vessels and at low levels in veins. 12 VEGF 165 is secreted, but a large quantity remains bound to the extracellular matrix and cell surface heparan-sulfate. Extracellular matrix-bound VEGF 165 can be released by heparin or heparinase, whereas cleavage of VEGF 165 by plasmin releases the growth factor domain from the matrix and yields a polypeptide dimer of 34 kDa that can act as a mitogen. 13, 14 VEGF 165 is the most potent angiogenic VEGF isoform, for example, when delivered via an adenovirus to mouse skin. 15 In contrast, mouse VEGF 120 (corresponding to human VEGF 121 ) lacking the heparin and neuropilin-binding domain cannot substitute for the endothelial guidance function of the larger VEGF isoforms. 16, 17 VEGF 189 , on the other hand, binds to neuropilins and to heparin very tightly. Depending on the target tissue, VEGF has also been found to induce hyperplasia of lymphatic vessels. 15,18 -20 VEGF-C and VEGF-D do not bind to heparin. 5 These factors have CT domains homologous to certain silk proteins, and shorter amino-terminal (NT) propeptides. 21 Proteolytic cleavage between the growth factor domain and the CT silk homology domain increases the affinity of VEGF-C to VEGFR-3, whereas the NT-cleaved mature form (VEGF-C⌬N⌬C) can also activate VEGFR-2 in blood vessel endothelial cells, resulting in angiogenic activity. 5, [22] [23] [24] [25] Like VEGF, VEGF-C and VEGF-D also interact with NP-1 and NP-2. 26 We hypothesized that combining the receptor-activation properties of VEGF with the propeptides of VEGF-C would yield additional information about the biological role of these peptides and possibly result in novel vascular patterns in vivo. In this study, we created a novel chimeric protein, VEGF-CAC, in which the NT propeptide and the CT silk homology domain of VEGF-C flank the VEGF homology domain (VHD), ie, the minimal receptor-binding domain of VEGF, thus replacing the heparin-binding domain. We compared the angiogenic and lymphangiogenic effects of VEGF-CAC with those of VEGF 165 , and with VEGF 109 , which contains only the VHD.
Materials and Methods

Cell Culture
293T (human kidney) and HeLa cells from the American Type Culture Collection (Manassas, Va) were maintained in DMEM (HaartBio, Helsinki, Finland) supplemented with 2 mmol/L L-glutamine (HaartBio), 0.2% penicillin/streptomycin sulfate, and 10% FBS (PromoCell, Heidelberg, Germany). Ba/F3 (murine pro-〉) cells expressing a chimeric VEGFR-1/erythropoietin receptor (EpoR) or a VEGFR-2/EpoR were grown in DMEM supplemented with 200 g/mL Zeocin (Invitrogen, Carlsbad, Calif) and recombinant mouse interleukin-3 (Calbiochem, San Diego, Calif). 27, 28 Constructs cDNA encoding the CAC fusion protein was produced by PCR amplification and subcloning of the NT and CT sequences of human VEGF-C cDNA and their ligation to the human VEGF VHD cDNA. The resulting cDNA was flanked with sequences coding for a His 6 tag (3Ј end) and the mouse immunoglobulin kappa signal peptide (5Ј end). The cDNA sequence was verified and inserted into the pMosaic vector. 29 The VEGF-CAC cDNA was cut from pMosaic with AgeI and ClaI and blunted and ligated into the psub-CMV-WPRE AAV2 plasmid. 30 The cDNA for VEGF109, comprising amino acids 37 to 135 of the VEGF VHD (UniProtKB/SwissProt P15692), was amplified with the primers 5Ј-GCGGATCCGGGGCAGAATCATCACGAAGTGG-TG-3Ј and 5Ј-GCGGATCCCTAATCTTTCTTTGGTCTACATTC-ACAT-3Ј using the CAC/psub-CMV-WPRE AAV2 plasmid as a template. The obtained cDNA fragment was digested with BamHI and cloned into the BamHI site of the pMosaic vector.
Production and Analysis of Adenoviral Vectors
The cDNAs encoding VEGF-CAC and VEGF 109 were cloned into the pAdBglII vector, and recombinant adenoviruses were produced as described previously. 31 For analysis of protein production, HeLa cells were transduced with the adenoviruses AdCAC, AdVEGF 165 , AdVEGF 109 , or AdLacZ (100 virus particles per cell). Expression of the recombinant proteins was examined by metabolic labeling of the transduced cells and immunoprecipitation from conditioned media, followed by SDS-PAGE and autoradiography.
Transfections and Immunoprecipitations
293T cells were transfected with psub-CMV/CAC, psub-CMV/ VEGF 165 , psub-CMV/VEGF 109 , pEBS7/VEGF-C, or the empty pEBS7 vector using JetPEI (Qbiogene, Irvine, Calif) according to the specifications of the manufacturer. Transfected cells were cultured for 48 hours and metabolically labeled in methionine-and cysteinefree medium supplemented with [ 35 S]methionine and [ 35 S]cysteine (Redivue ProMix, Amersham Biosciences, Uppsala, Sweden) at 100 Ci/mL for 16 hours. Conditioned medium was collected, cleared by centrifugation, supplemented with 5% BSA and 0.02% Tween-20, and incubated with anti-human VEGF (AF293NA, R&D Systems, Minneapolis, Minn) or anti-human VEGF-C (AF752, R&D Systems). Alternatively, 1 ml of the conditioned medium was incubated with 200 ng of soluble VEGFR-1-Ig 28 or VEGFR-2-Ig 30 or incubated with neuropilin-Ig fusion proteins 26 with or without the addition of 10 g/mL heparin (GIBCO BRL/Invitrogen). The neuropilin-Ig fusion proteins were produced in 293T cells transiently transfected with the corresponding expression vectors. 26, 32 The complexes were then bound to protein A-sepharose or protein G-sepharose (Amersham Biosciences), followed by washing 3 times with 0.5% bovine serum albumin and 0.02% Tween-20 in PBS and once with PBS. Proteins were separated by SDS-PAGE under reducing or nonreducing conditions and visualized by autoradiography.
Pulse-Chase Analysis
Transiently transfected 293T cells were metabolically labeled for 30 minutes and then chased in nonradioactive medium for different time periods. The conditioned media were supplemented with 5% BSA and 0.02% Tween-20, and recombinant VEGF proteins were immunoprecipitated. Antigen-antibody complexes were analyzed under reducing conditions.
Bioassay for Growth Factor-Mediated Cell Survival
HeLa cells (10 6 ) were seeded on 10-cm plates and transduced with AdVEGF-CAC, AdVEGF 109 , AdVEGF 165 , or AdLacZ. After 24 hours, the transduced cells were serum starved for 16 hours; after which time, medium was collected, centrifuged at 2500 rpm for 5 minutes and stored at 4°C. To compare expression levels of the different constructs, conditioned medium was mixed with Laemmli sample buffer, heated for 5 minutes at 95°C and separated in 12% SDS-PAGE gels (Ready-Gel, Bio-Rad). Proteins were transferred to a nitrocellulose membrane, blocked with 5% BSA, and incubated with anti-VEGF. Biotinylated rabbit anti-goat and streptavidinhorseradish peroxidase were used as secondary antibodies. Bound antibodies were visualized using the Femto ECL reagent (Amersham) according to the instructions of the manufacturer.
Ba/F3 cells expressing the VEGFR-1/EpoR 28 or VEGFR-2/EpoR chimeric receptor 27 were seeded into 96-well plates at the density of 20 000 cells per well in triplicates and supplied with different dilutions of conditioned medium from HeLa cells. Cell viability was quantified after 48 hours by a colorimetric assay. Briefly, 0.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Sigma-Aldrich, St Louis, Mo) was added into each well and incubated for 2 hours at 37°C. The reaction was terminated by adding lysis buffer (10% SDS/10 mmol/L HCl), and the resulting formazan products were solubilized overnight at 37°C in a humid atmosphere. The absorbance at 540 nm was measured using a Multiscan microtiter plate reader (Thermo Labsystems, Milford, Mass).
In Vivo Analysis of Adenoviral Vectors
Approximately 2ϫ10 8 pfu of AdVEGF-CAC, AdVEGF 109 , Ad-VEGF 165 , or AdLacZ were injected subcutaneously into the ears of NMRI nu/nu mice (Taconic Europe, Mollegaard, Denmark). Two weeks after adenoviral gene transduction, the mice were anesthetized and then perfused with 1% paraformaldehyde for 2 to 3 minutes. The
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Enhanced Angiogenesis by a VEGF/VEGF-C Chimera ears were collected, immersed in 4% paraformaldehyde for 2 hours, and dissected for whole-mount staining. Alternatively, the ears were embedded in OCT medium (TissueTek, Sakura Finetek, Zoeterwoude, The Netherlands), frozen, and cut into 6-m sections. The tissues were blocked with 5% normal goat or donkey serum in 0.3% Triton X-100 (Fluka Biochemika, Steinheim, Switzerland) in PBS. For staining of blood vessels in the ear, tissues were incubated overnight with a monoclonal hamster anti-mouse platelet endothelial cell adhesion molecule (PECAM)-1 antibody (clone 2H8, Chemicon, Temecula, Calif). Perfused blood vessels were visualized by injecting the mice intravenously with 1 mg of fluorescein isothiocyanate (FITC)-conjugated Lycopersicon esculentum lectin (LE-lectin) (Vec-torLabs, Burlingame, Calif) in 200 L of PBS, followed by perfusion fixation with 1% paraformaldehyde. For detection of smooth muscle cells, staining was performed with antibodies for smooth muscle actin (clone 1A4, C6198, Sigma). Basement membranes of blood vessels were stained with monoclonal rat antibodies against nidogen/entactin (Chemicon), and pericytes with monoclonal rabbit antibodies against neuron-glial protein 2 (NG2, Chemicon), whereas lymphatic vessels were visualized with rabbit antiserum against the lymphatic endothelial-specific hyaluronan receptor LYVE-1. 33 Semimembraneous muscles of rabbit hindlimbs were adenovirally transduced with AdVEGF-CAC, AdVEGF 109 , AdVEGF 165 , and Ad-LacZ and analyzed as described previously. 34 All experimental procedures involving laboratory animals were approved by the Provincial State Office of Southern Finland (mice) and Eastern Finland (rabbits).
Quantitative Analysis
ImagePro Plus version 6.0 software (Media Cybernetics Inc, Silver Spring, Md) was used to quantify the LE-lectin-perfused vessel area and the area of PECAM-1-positive endothelium. Vessels surrounded by vascular mural cells were counted as PECAM-1-positive vessels that were in contact with NG2-positive pericytes, or smooth muscle actin-positive smooth muscle cells. The cross-sectional surface area of capillaries in rabbit semimembranosus muscle was counted from PECAM-1-stained sections. All quantifications were counted from three ϫ400 microscopic fields in each ear section and at least 3 sections from each ear or muscle, and the analytical technique and time point were analyzed. Data are expressed as meanϮSD (nϭ4 to 10 mice per group).
Results
Proteolytic Processing and Receptor Binding and Activation Properties of the VEGF-CAC Chimera
To analyze the functions of the VEGF-C propeptides, we cloned the VEGF-CAC construct comprising the minimal receptor-binding domain (VHD or VEGF 109 ) of VEGF between the NT and CT propeptides of VEGF-C ( Figure 1A) . For comparison, we used VEGF 165 and VEGF 109 as controls throughout the study. The factors produced by the constructs were analyzed by binding of the 35 S-labeled conditioned medium from transiently transfected 293T cells to the soluble extracellular domains of the VEGF receptors. As shown in Figure 1B , the VEGF 109 protein bound to VEGFR-1 and VEGFR-2 but not significantly to the neuropilins, whereas the VEGF-CAC protein bound also to the neuropilins. Interestingly, the VEGF-C propeptides did not inhibit VEGF-CAC binding to VEGFR-1 or VEGFR-2, although they are known to severely reduce VEGF-C and VEGF-D binding to VEGFR-2. 5 Heparin greatly increased the binding of VEGF-CAC to both neuropilins; interaction especially with NP-2 was almost undetectable in the absence of heparin ( Figure  1B) . In nonreducing conditions, the full-length VEGF-CAC migrated as an Ϸ100-kDa polypeptide band ( Figure 1C ), indicating that it formed disulfide-linked dimers.
VEGF-CAC protein processing was analyzed by pulsechase labeling and immunoprecipitation with anti-VEGF-C antibodies. VEGF-CAC and VEGF-C were secreted as 66and 68-kDa polypeptides, respectively. 5 Both were processed in a similar manner into doublets of approximately 29 and 31 kDa containing the 31-kDa CT part and the 29-kDa NT part, together with the VHD. Gradually, small amounts of the 20-kDa mature forms containing the VHD were generated from both polypeptides ( Figure 1D ). The unprocessed forms of neither protein were detected after 24 hours, indicating that they were effectively processed.
Both AdVEGF-CAC and AdVEGF 109 bound to VEGFR-1 and VEGFR-2 but not to VEGFR-3 ( Figure 2A ). The ability of the adenovirally produced factors to dimerize their receptors was tested in the Ba/F3-VEGFR-1/EpoR and Ba/F3-VEGFR-2/EpoR cells. The growth and survival of these cells depends on the dimerization of the respective receptors and activation of the intracellular domain of EpoR. Expression levels of AdVEGF-CAC and AdVEGF 109 in the conditioned media of adenovirustransduced HeLa cells were approximately equal ( Figure  2B) , and both media activated VEGFR-1 and VEGFR-2 in roughly similar dilutions, but they did not activate VEGFR-3 ( Figure 2C and data not shown) . These data indicated that both factors were capable of receptor binding and activation.
VEGF-CAC Induces Angiogenesis and Lymphatic Vessel Dilation In Vivo
To assay the biological activity of VEGF-CAC in vivo, AdVEGF-CAC was injected into rabbit hindlimb skeletal muscle and into the ears of nude mice. AdVEGF-CAC induced a 37.5-fold increase and AdVEGF 109 a 50.7-fold increase in cross-sectional capillary surface area compared with AdLacZ controls (PϽ0.01), whereas the increase in AdVEGF 165 -transduced muscle was 20.1-fold (PϽ0.01), which was significantly less when compared with AdVEGF-CAC or AdVEGF 109 (PϽ0.05) ( Figure 3A 
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Whole-mount preparations of AdVEGF-CAC-transduced ears stained with antibodies to nidogen/entactin and PECAM-1 showed a prominent increase in thin basement membrane tubes that contained endothelial cells ( Figure 4A through 4C), when compared with the ears treated with the other 2 factors (Figure 4D through 4I ). The major difference between AdVEGF-CAC-and AdVEGF 109 -or AdVEGF 165transduced vessels was the striking pattern that was a homogenous network in the former and an uneven tree-like hierarchical branching, containing new sprouts in the latter 2 sets of vessels.
The AdVEGF-CAC-induced angiogenesis was also accompanied by vessel investment by smooth muscle cells. We found that 71.0% (SEM, Ϯ14.8%) of the blood vessels had smooth muscle cell coverage in VEGF-CAC-transduced ears, whereas fewer such vessels were observed in VEGF 165transduced (40.7Ϯ10.7%), VEGF 109 -transduced (33.3Ϯ13.0%), or LacZ-transduced (40.8Ϯ14.7%) ears (PϽ0.05). Furthermore, most of the VEGF-CAC-generated vessels were coated with pericytes, which were visualized with antibodies against neuron-glial protein 2 ( Figure 4M  through 4T ). We observed that 70.6% (Ϯ3.7%) of blood vessels were surrounded by pericytes in VEGF-CAC-transduced ears, whereas the proportion of pericyte-covered ves-sels was significantly less in VEGF 165 -transduced (24.0Ϯ5.8%) or VEGF 109 -transduced (48.3Ϯ4.4%) ears (PϽ0.05). The proportion of vessels encircled by pericytes in VEGF-CAC ears was similar to that observed in ears after LacZ transduction (62.2Ϯ5.8%), reflecting a normal degree of vessel stabilization in VEGF-CAC-transduced ears.
The AdVEGF-CAC-Induced Vessels Are Functional
To visualize perfused blood vessels, the mice were injected intravenously with fluorescent L esculentum (tomato) lectin, which binds to N-acetyl-D-glycosaminoglycan in blood vascular endothelial cells. Mouse ears transduced with AdVEGF-CAC showed a dramatic increase in the number of lectin-positive vessels when compared with the 2 other VEGFs, although some of the PECAM-1-positive endothelium remained lectin negative in all cases ( Figure 5 ). Areadensity quantification of LE-lectin and PECAM-1-positive vessels from the different ear sections is shown in Figure 5M and 5N, with the ratio of lectin-perfused vessels to PECAM-1-stained vessels in each case in Figure 5O .
Discussion
We report here the generation and biological characterization of VEGF-CAC, a chimeric VEGF comprising the receptoractivating domain of VEGF flanked by the propeptides of VEGF-C. VEGF-CAC is secreted and processed in a manner similar to VEGF-C, and it induces angiogenesis in a pattern distinct from VEGF.
In vitro, VEGF-CAC was a potent inducer of the proliferation/survival of BaF3 cells expressing chimeric VEGF receptors, whereas in vivo overexpression of the factor led to robust angiogenesis that was shown to exceed even the angiogenic activity of VEGF 165 . This increase in biological activity may be attributable to the greater solubility of the immature VEGF-CAC when compared with VEGF 165 , as VEGF-CAC does not have a heparin-binding domain. The architecture of the vessels formed in response to adenoviral overexpression of VEGF-CAC differed from that induced by VEGF 165 . VEGF-CAC induced a more homogenous network of perfused, pericyte-and basal lamina-coated capillaries, instead of a more hierarchical structure of vessels of differing sizes in a treelike branching pattern generated by VEGF 165 . VEGF 165 stimulates angiogenesis through capillary sprouting by inducing concentration-gradient-guided migration of endothelial cells. 17, 35 This coordinated action is apparently attributable to the intermediate heparin-binding properties of VEGF 165 , when compared with VEGF 121 and VEGF 189 . VEGF bioavailability is regulated extracellularly by matrix metalloproteinases through intramolecular processing and subsequent release from the matrix. An elegant study by Lee et al showed that a mutant matrix metalloproteinase-resistant VEGF supported extensive growth of thin vessels with multiple and frequent branch points. 36 According to their findings, matrix-bound VEGF and nontethered VEGF provided different signaling outcomes and vascular patterning. 36 It is possible that VEGF-CAC promotes extensive development of thin-capillary-sized vessels because most of this growth factor is only partially processed, with a retention of the silk homology domain that, like silk, could have a structural function in the pericellular matrix. 37 Interestingly, the newly formed capillaries were abundantly covered with pericytes, which are known to stabilize blood vessels via angiopoietin-1 38, 39 and sphingosine-1-phosphate signals, 40 indicating that the vessels were more functional, stabile and mature than those generated by VEGF 165 or VEGF 109 . 
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In addition to its angiogenic activity, VEGF-CAC was shown to induce circumferential dilation of cutaneous lymphatic vessels. Consistent with our results, overexpression of VEGF has been shown to induce large, hyperplastic lymphatic vessels. 15, 18, 19 These signals may be mediated via VEGFR-2, which is also expressed in lymphatic endothelial cells. 6, 20 The effects of VEGF-CAC on lymphatic vessels could be at least partly attributable to increased fluid accumulation as a result of VEGFR-stimulated blood vessel leakiness.
Both VEGF and VEGF-C are well-characterized growth factors, and a wealth of knowledge about their biological functions exists. 1 However, knowledge about the biological function of VEGF-C propeptides has remained scarce, whereas the role of the heparin-binding domains of VEGF has been abundantly studied. 1 Our approach to study VEGF-C propeptides by swapping domains between growth factors has led previously to generation of novel and particularly potent growth factor variants. For example, replacement of the NT oligomerization domain of angiopoietin-1 with the N terminus of angiopoietin-2 yielded a more soluble and active growth factor, designated Ang1*. 41 Furthermore, linkage of the heparin-binding domain of VEGF 165 to VEGF-E resulted in a heparin-binding form of VEGF-E (hbVEGF-E), which was able to stimulate proliferation and sprouting of endothelial cells. 42 In a binding competition assay, hbVEGF-E was more potent than VEGF-E, which may have been caused by binding to the NP-1 coreceptor. 42 As VEGF-CAC proved to potently promote the formation of new capillaries with a distinct morphology, we envision significant potential for such domain-swap combinations in biotechnology applications in the future.
